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The adaptive immune response forms the basis of allograft rejection. Its weapons are direct
cellular cytotoxicity, identiﬁed from the beginning of organ transplantation, and/or anti-
bodies, limited to hyperacute rejection by preformed antibodies and not as an allogenic
response. This resulted in allogenic response being thought for decades to have just a cellu-
lar  origin. But the experimental studies by Gorer demonstrating tissue damage in allografts
due  to antibodies secreted by B lymphocytes activated against polymorphic molecules were
disregarded.
The special coexistence of binding and unbinding between antibodies and antigens of
the  endothelial cell membranes has been the cause of the delay in demonstrating the
humoral allogenic response. The endothelium, the target tissue of antibodies, has a high
turnover, and antigen–antibody binding is non-covalent. If endothelial cells are attacked by
the  humoral response, immunoglobulins are rapidly removed from their surface by shedding
and/or internalization, as well as degrading the components of the complement system by
the  action of MCP, DAF and CD59. Thus, the presence of complement proteins in the mem-
brane of endothelial cells is transient. In fact, the acute form of antibody-mediated rejection
was  not demonstrated until C4d complement fragment deposition was identiﬁed, which is
the  only component that binds covalently to endothelial cells.
This review examines the relationship between humoral immune response and the types
of  acute and chronic histological lesion shown on biopsy of the transplanted organ.©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).∗ Corresponding author.
E-mail address: mgonmol@yahoo.es (M. González-Molina).
http://dx.doi.org/10.1016/j.nefro.2016.03.023
0211-6995/© 2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Respuesta  inmune  e  histología  de  rechazo  humoral  en  el  trasplante  renal
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r  e  s  u  m  e  n
La respuesta inmune adaptativa constituye la base del rechazo del aloinjerto. Sus armas lesi-
vas  son la citotoxicidad celular directa o los anticuerpos. La primera, identiﬁcada desde los
inicios del trasplante de órganos y la segunda, limitada al rechazo hiperagudo por anticuer-
pos  preformados y no como respuesta alogénica. Ello permitió mantener durante décadas
que  la respuesta alogénica tenía solo un origen celular. Pero se ignoraron los trabajos exper-
imentales de Gorer que demostraban dan˜o tisular en aloinjertos por anticuerpos secretados
por  linfocitos B activados frente a moléculas polimórﬁcas.
La especial convivencia de unión y desunión entre anticuerpos y antígenos de membrana de
células endoteliales ha sido la causa que retrasó la demostración de la respuesta alogénica
humoral. El endotelio, que es el tejido diana de los anticuerpos, tiene un turnover alto y la
unión antígeno-anticuerpo no es covalente. Si las células endoteliales sufren el ataque de
la  respuesta humoral, eliminan rápidamente de su superﬁcie las inmunoglobulinas medi-
ante shedding o internalización y, a la vez, degradan los componentes del complemento
por  la acción de MCP, DAF y CD59. Así, la presencia de las proteínas del complemento en
la  membrana de las células endoteliales es pasajera. De hecho, la forma aguda de rec-
hazo por anticuerpos no se demostró hasta identiﬁcar el depósito del fragmento C4d del
complemento, que es el único de unión covalente a las células endoteliales.
Esta revisión analiza la relación entre la respuesta inmune humoral y los tipos de lesión
histológica aguda y crónica de la biopsia del órgano trasplantado.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo  Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licencias/
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tive or acquired immune response, consisting of T andntroduction
enal biopsy is the gold standard diagnostic test for acute
ejection (AR) after renal transplantation (RT). Distinctively,
t shows an inﬁltration of mononuclear cells (T lympho-
ytes), considered speciﬁc by the Banff classiﬁcation when
t affects the tubules (tubulitis) and/or the endothelium
endothelitis).1,2 Based on this, during the ﬁrst four decades
f RT, the cell theory remained the sole theory for AR, and
umoral response was limited to hyperacute rejection, caused
y preformed antibodies against HLA class I antigens and not
econdary to the response of the recipient.3,4
However, during this long time the experimental work of
orer was unknown. His studies demonstrated the formation
f antibodies against H-2 histocompatibility antigens in 21 of
2 mice, after implantation of allogeneic sarcoma cells and
n skin allografts, in response to antigen stimulation.5–7 Addi-
ionally, Morris showed the presence of cytotoxic antibodies
ollowing RT in man.8
Not until the early 1990s did Feucht show the pres-
nce of C4d deposits in peritubular capillaries as a mark
f complement system activation by the action of anti-HLA
ntibodies.9,10 Subsequently, the work of Terasaki11,12 and
he successive contributions of the Banff classiﬁcation13,14
leared the way for the diagnosis of humoral AR. Although
oubts remain about the cell and molecular pathways regu-
ating antibody-mediated rejection, current understanding of
heir immunobiology shows that activation of B lymphocytes
nduced by polymorphic molecules (HLA or non-HLA) results
n the formation and secretion of donor-speciﬁc antibodies
DSA) that damage the allograft.15,16 This review examines theby-nc-nd/4.0/).
relationship between the immune response and the histology
of humoral rejection in RT.
Immune  system
The foundations of what is now known as the humoral
immune response were established millions of years ago when
the ﬁrst living beings shared their habitat with pathogens that
posed a threat to their survival. This evolutionary challenge
led to the creation of a defense infrastructure known as the
immune system (IS).17
The most elementary invertebrates developed an IS similar
to phagocytosis and the more  complex invertebrates devel-
oped an IS composed of molecules (cytokines, complement
system and acute phase proteins) and eminently phagocytic
cells (neutrophils, monocytes, macrophages, eosinophils,
basophils, mast cells, natural killer [NK] and dendritic cells).
These lacked immunological memory,  had limited progeny,
a relatively long life and high efﬁciency receptors encoded
in the germline, which only recognized microorganism struc-
tures called “pathogen-associated molecular patterns”; they
were therefore unable to recognize other molecular differ-
ences. This response is known as innate immunity.18
Evolutionary pressure, in a continuous process of “adapt
or die”, allowed vertebrates to complete their IS, adding a
new identiﬁcation and defense infrastructure known as adap-
18,19B lymphocytes. The distinctive element of this system is
its ability to generate membrane receptors by random gene
rearrangements; representing a high capacity to form very
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many  different receptors that can recognize a wide variety of
antigens. These cells are also equipped with immunological
memory  and the ability to proliferate, on encountering a recog-
nized antigen, and form a clone with a speciﬁc receptor. Thus,
their repertoire in the total population is so broad that there is
an increased probability that an antigen will present to a par-
ticular lymphocyte, bind to its receptor and induce activation
and proliferation. This process is known as clonal selection
and is a basic feature of the adaptive immune response for
recognition of molecular differences; in our case, provided by
the allograft.
Given the large number of cells and molecules forming the
IS, its ability to recognize and respond is very varied and is
carried out by neutralization, opsonization, phagocytosis and
humoral and cell lysis. The IS uses the most effective mecha-
nism for each threat.
Which of these mechanisms comprise the most effective
response against an allograft? Neutralization and cellular and
humoral lysis; precisely, the mechanisms that the IS launches
against viruses.
Humoral  response
Brain death and ischemia induce an inﬂammatory response
characterized by an inﬁltration of polymorphonuclear cells
and macrophages, with increased expression of selectins
and complement factors C3a and C5a.20 The cells injured
by ischemia release materials (damage-associated molecular
patterns – DAMPS), which are ligands of Toll receptors. Epithe-
lial, endothelial and mesenchymal cells have Toll receptors
that, stimulated by their ligands, are the starting point of bio-
chemical signals that activate the innate immune response.21
Damaged endothelial cells alter their permeability and anti-
coagulant function, and the altered molecules induce an
inﬂammatory response and complement activation (in this
case via the lectin pathway).22
DAMP molecules stimulate the dendritic cells that process
and express donor HLA antigens in their molecules. In con-
clusion, the allograft carries a load of activity of the innate
immune response that intensiﬁes after implantation through
ischemia-reperfusion,23,24 a process that is the precursor to
the adaptive immune response of the recipient, which pro-
vokes allograft rejection.
The allogeneic humoral response is initiated by allograft-
antigen recognition by the activated B cell that proliferates to
form an antigen-speciﬁc clone, which actively secretes anti-
bodies and generates memory  cells.25
Several B cell activation pathways exist (independent of
Th lymphocytes and vs disaccharides), but it is the Th
cell-dependent pathway that is associated with allogeneic
transplant. This pathway characterizes responses to proteins
such as HLA. These responses require ligation of the antigen
receptor plus the delivery of T-cell help, particularly through
CD40/CD40 ligand interactions.25
Since B cell activation leads to the formation and secretion
of antibodies as a harmful weapon, its detection in blood is
used to assess humoral response. But, surprisingly, although
the detection technique has been perfected,26 the presence of
antibodies against HLA antigens is low in the ﬁrst phase of3  6(4):354–367
transplantation, despite immunosuppressive therapy that is
more  effective against T cells than B cells. Some have inter-
preted this as a reﬂection of the lack of a B-cell response to
allogeneic stimulation,27 and others as the possibility that
the response is higher and that antibodies are absorbed and
cleared by the allograft.28
A more  direct procedure for assessing allogeneic humoral
response by calculating the frequency of antibody-secreting
B cells using the ELISPOT technique has been proposed. A
trial of this method in recipients of allogeneic RT, using as
a target ﬁbroblasts cultured from the donor instead of puri-
ﬁed antigens, showed that although none of the nine patients
in the study had DSA in serum before or after transplan-
tation, all exhibited an increased number of DSA-secreting
cells directed against donor HLA class I antigens eight weeks
post-transplant. This supports the concept that the allogeneic
humoral response is more  frequent than what is deduced by
the detection of antibodies in blood.29
Infrastructure  of  the  humoral  response
The Banff classiﬁcation bases diagnosis of humoral AR on the
presence of serum DSA, on histological criteria of acute tissue
damage of the vascular wall (intimal or transmural arteritis
and acute thrombotic microangiopathy) and on the interac-
tion between antibodies and the vascular endothelium (C4d
deposition in peritubular capillaries, microvascular inﬂam-
mation and increases in endothelial activity and endothelial
activation and transcripts (ENDATs).30,31
The speciﬁc infrastructure of the immune response
causing these histological lesions consists of B lympho-
cytes, antibodies (anti-HLA or others), inﬂammatory cells
(neutrophils, monocytes-macrophages and NK) and the com-
plement system and, as a target, the endothelial cells.
1. B lymphocyte. This is the cell that generates antibodies.
Two types of B lymphocyte antibody generators exist.32,33
B1 resides in the pleura and peritoneum and produces
low afﬁnity antibodies irrespective of the Th lymphocytes;
and B2 permanently circulates through the secondary lym-
phoid organs to ﬁnd an antigen that activates and expands
it (clonal proliferation). Once activated it interacts with the
Th lymphocyte receptor to present the antigen in HLA class
II molecules to it and activate it. In addition, the B cell
produces cytokines that stimulate the T cell. Thus, the B
lymphocyte plays a prominent role in the activation and
development of T memory  cells.34
The activated B lymphocytes form extrafollicular plas-
mablasts that produce low afﬁnity antibodies or migrate
to the germinal center where somatic hypermutation of
the variable-region immunoglobulin genes, immunoglobu-
lin class switching and plasma and memory  cell generation
manufacturing and secreting IgG antibodies originate. For
the germinal centers of the B cells to form, the presence of
follicular T lymphocytes is necessary.35Notably, in animal36 and human37 models of transplan-
tation the formation of tertiary lymphoid organs in the
allograft has been seen, suggesting that B cells can be acti-
vated directly in the transplanted organ.
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Fig. 1 – Non-covalent antigen–antibody binding regulated by hydrogen bonds and electrostatic, van der Waals and
hydrophobic forces. Structure of an IgG antibody. The antigen binding sites are formed by the juxtaposition of variable light
chain (VL) and heavy chain (VH) domains. The CH2 domain of the Fc region is the binding site for C1q or FcR  of
i . HC:
2nﬂammatory cells. CDRs: complementarity domain regions
A subpopulation of B cells inhibiting the immune response
has also been demonstrated.38 This regulatory function is
done by IL-10 secretion.
. Antibodies. These are glycoproteins with a heavy and light
double chain symmetrical structure, part of the defense
system against pathogens. In allogeneic RT they are
generated in response to antigenic stimuli caused by poly-
morphic molecular differences and have been described
against HLA, MICA,  ABO, vimentin, phospholipids, stress
proteins and the angiotensin II AT1 receptor in relation to
AR and chronic rejection.39 The most frequently generated
antibodies are against HLA molecules, because they are the
most polymorphic, and being expressed on the endothelial
cell membrane makes them very vulnerable.
Understanding the role of antibodies in RT requires focus-
ing its analysis on the following:
a. Immunoglobulin chains are joined together covalently.
This type of binding is formed by non-metallic atoms
with many  electrons in their periphery and a ten-
dency to attract even more;  each atom is attached to
another by exchanging an electron to form a very strong
bond.
b. Antigen binding to the antibody is noncovalent, but
is regulated by electrostatic forces, hydrogen bond-
ing and Van der Waals and hydrophobic forces
forming a reversible bond; temperature sensitive, anti-
gen/antibody proportional, pH and ionic strength of the
medium (Fig. 1). heavy chain.
c. The hinge region, located between the CH1 and CH2
domains, provides ﬂexibility to the immunoglobulin to
guide each of its arms to the antigen binding.
d. Fab region, comprising two antigen binding arms, each
formed in both the heavy and the light chain by one vari-
able and one constant domain. The variable is so called
because in each chain it has three segments of variabil-
ity formed by ten amino acid residues that differentiate
antibodies produced by one particular B cell clone from
another (Fig. 1).
The three variable segments of the heavy and light chains
combine to form a three-dimensional antigen binding sur-
face space. Since this surface is complementary to the
antigen binding region (like a key and lock), they are called
complementarity determining regions (CDRs) or CDR1, 2
and 3. Those with the greatest variability and antigen con-
tact are CDR3.
e. Fc region, consisting of two or three heavy chain con-
stant domains (Fig. 1), according to the immunoglobulin
serotype (three for IgM and two for the remainder) and
mediating the effector functions of the antibody on
binding to the C1q complement fraction and to cells
with Fc region receptors (FcRs) having a polypeptide
 chain with a polymorphic character that determines
binding to the Fc region.3. Inﬂammatory cells. The pathophysiology of humoral
AR begins with the binding of DSA to HLA and non-
HLA allograft antigens, expressed on the endothelial cell
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 inﬂa
 cellsFig. 2 – Acute humoral rejection. (A) Capillaritis. Presence of
capillaries (H&E). (B) Glomerulitis. Presence of inﬂammatory
membrane. This process generates two-way attraction and
activation of inﬂammatory cells (neutrophils, macrophages
and NK cells):
a. Complement dependent. Complement activation by
cytotoxic antibodies bound to the HLA antigen of the
endothelial cell membrane generates the C3a and C5a
fractions, which are potent opsonins. By chemotactic
gradient, they attract inﬂammatory cells to the per-
itubular (capillaritis) (Fig. 2A) and glomerular capillaries
(glomerulitis) (Fig. 2B) and activate them through inter-
action with their cognate receptors (C3aR and C5aR) to
secrete enzymes and pro-inﬂammatory cytokines.
b. Complement independent. IgG isotype antibodies act as
ligands for endothelial cell membrane molecules of the
glomerular and peritubular capillaries and are bound by
the CH2 domain of the Fc region to inﬂammatory cells
having FcRIII that induce antibody-mediated cell lysis.
The role of NK cells in antibody-mediated cytotoxicity
should be emphasized. Once bound to the CH2 domain of
the Fc region by their FcRIII, they are activated and secrete
INF- and the content of their granules with which they
cause cell lysis.
4. Complement system. Activation of the classical comple-
ment pathway following an episode of humoral response in
allograft organ transplantation is initiated by the binding of
the ﬁrst fragment, C1q, to the CH2 domain of the Fc region
of the IgG isotype immunoglobulins. Not all IgG subclasses
activate it; only IgG3 and IgG1 (in order of intensity), IgG2
does so weakly and IgG4 has no reactivity.40 This difference
is determined by the CH2 domain polymorphism.
Based on protein engineering studies of mouse IgG2b, three
charged amino acids (glycine 318, lysine 320 and lysine 322)
located on one  strand of CH2 were proposed as constitut-
ing the essential C1q binding motif.41 But the binding is notmmatory cells (polynuclear leukocytes) in peritubular
 (macrophages) in glomerular capillaries (PAS).
sufﬁcient to activate complement, because this motif is
present in all IgG subclasses. It needs something else.
Studies with mutants of IgG subclasses have shown that
the presence of lysine at position 276, very close to the bind-
ing motif of C1q (glycine 318, lysine 320 and lysine 322) gives
the IgG3 its ability to initiate complement activation and in
IgG1 the presence of proline at position 291. In contrast, IgG4 is
unable to activate complement, despite binding to C1q, due to
the presence of a serine residue at position 331. This conﬁrms
that C1q binding to the CH2 domain of the Fc region of the
immunoglobulin only is not sufﬁcient to activate complement,
but rather the presence of certain amino acids at various pos-
itions in the CH2 domain of the Fc region determines whether
or not the IgG subtype activates it.41,42
IgG antibodies have a longer half-life than other pro-
teins because the neonatal Fc receptor binds to the IgG
after being endocytosed by the cell and instead of being
degraded is recycled to the cell surface.43 Mice with a deﬁcit
of neonatal Fc receptor have decreased circulating IgG lev-
els and a reduced immunoglobulin half-life. Immunoglobulin
administration to treat humoral rejection has among other
properties that of binding to neonatal receptors and saturat-
ing them, thereby inhibiting the interaction of endogenous
IgG antibodies with the neonatal Fc receptor, favoring their
disappearance.44
In addition to the chemotactic function cited, complement
has the following functions:
a. C3b, iC3b and C3d opsonins promote cell lysis.
b. The membrane attack complex (C5b-9) lyses cells or
opsonized pathogens.
c. Experimental models have shown that uncontrolled com-plement activation increases the T-cell reactivity through
costimulatory signals on antigen-presenting cells and T
lymphocyte allograft-antigen recognition.45,46
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. The C3a and C5a fractions stimulate differentiation of Th0
into Th1 cells; and C3aR and C5aR signaling inhibits devel-
opment of regulatory T cells.47
. Allograft cells that are opsonized by complement frac-
tions have greater interaction with T cells, suggesting that
complement-mediated cell adhesion may be important in
tissue damage mediated by T cells.48
The onset of formation of antibodies against allograft anti-
ens is complement-dependent.49,50
ntibody  target  cell
ndothelial cells are the antibody targets in the humoral
esponse. Thus, humoral rejection is a model of endothelial
ysfunction.
Endothelial cells form a functional unit with the underly-
ng smooth muscle cells and interstitial matrix. They control
assage of solutes, macromolecules and blood cells to tissues.
his process is regulated by molecules which increase (his-
amine, thrombin, TNF-, bradykinin, etc.) or lower (heparan
ulfate, prostaglandins, catecholamines, natiuretic peptide, -
drenergic receptor stimulators, etc.) vascular permeability.
They also contribute to the hemostatic balance by sepa-
ating plasma coagulation factors from coagulation activators
resent in the interstitial matrix secreted by smooth mus-
le cells. If the barrier effect is damaged, they are exposed to
ach other, initiating a process of activation of plasma fac-
ors IX and X by the VIIa tissue complex; and in response
o thrombin, platelets express receptors for the von Wille-
rand factor and platelet aggregation is activated. In this
ay, damage to the vessel wall eventually causes thrombotic
icroangiopathy. The kidney has a large area of endothelium
n the peritubular capillaries and glomeruli, which will suf-
er the most signiﬁcant damage by the action of antibodies.
he induction pathways by which antibodies cause injury to
ndothelial and smooth muscle cells are still being studied,
lthough more  is known about those caused by class I than by
lass II antibodies.
hy  have  there  always  been  difﬁculties
iagnosing  acute  humoral  rejection?
ndothelial cells express HLA class I antigens natively on their
embranes and after stimulation with INF- class II; and the
idney has a large endothelial surface on its peritubular and
lomerular capillaries upon which the anti-HLA antibodies
ay act.
The question in autoimmune glomerular diseases is, why
ere there no serious difﬁculties proving their autoimmune
rigin by biopsy, but why are there difﬁculties diagnosing
umoral AR? The response requires that the pathophysio-
ogical differences and, especially, the target tissue and its
urnover must be considered. In autoimmune glomerular dis-
ases, in addition to their pathophysiological differences,
mmune complexes are located in low turnover tissues such
s the subendothelium in lupus nephritis or in the base-
ent membrane in Goodpasture syndrome and membranous
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glomerulonephritis. Immune complexes are retained for long
periods in these low-turnover tissues, long enough to be
revealed on renal biopsy.
In humoral AR, however, antibodies are directed against
HLA antigens of endothelial cells, which have a high turnover.
If they are attacked by the humoral response they can
quickly remove surface immunoglobulins by shedding and/or
internalization51,52; and at the same time inhibit the activation
of the complement system in the early stages of the pro-
cess and in the late stages degrade their components by the
action of membrane cofactor protein53 (MCP), decay accelerat-
ing factor54 (DAF) and CD5955 (Fig. 3). Therefore, the presence
of complement proteins in the endothelial cell membrane is
transient; and since the onset of immune damage precedes
clinical signs of rejection, when the biopsy is performed the
humoral origin of the attack is not detected.
How did the C4d technique enable diagnosis of humoral
AR? Because this complement fraction binds to endothelial
cells covalently through a thio-ester bond to form a stable
bond, resistant to shedding. This is quite the opposite of
what happens with the C4c fragment, which degrades quickly.
Therefore, C4d deposition could demonstrate the presence of a
previously undetectable humoral response (Fig. 4). Neverthe-
less, the latest Banff classiﬁcation considers as histological
data of acute or chronic humoral AR evidence of endothe-
lial damage by the interaction of antibodies on endothelial
cells in patients with circulating DSA.13 It thus recognizes the
evidence of humoral rejection with negative C4d.30 The rea-
soning has been if the antibodies act on endothelial cells, they
can stimulate the expression of activation genes (ENDATs)
that produce transcripts that can be determined by microar-
rays. In this way, a phenotype of humoral rejection could
be identiﬁed with circulating antibodies with negative C4d.
Thus, kidneys with a high expression of ENDATs in the graft
and cytotoxic anti-HLA antibodies in blood showed histologi-
cal lesions compatible with antibody-mediated rejection. The
conclusions are: a high expression of ENDATs with circulat-
ing antibodies predicts graft loss with higher sensitivity (77 vs
31%) and lower speciﬁcity (71 vs 94%) than the presence of C4d.
However, high ENDAT expression was not an indicator of graft
damage or eventual graft loss in patients who  lacked anti-HLA
antibodies.56
Antibodies  and  histologic  lesions  in  allogeneic
transplant
Cytotoxic antibodies in organ transplantation cause endothe-
lial damage by Fig. 5:
1. Activation of the complement system.
2. Direct action.
3. Recruitment of inﬂammatory cells via Fc receptors
(antibody-mediated cell immunity).Activation  of  the  complement  system
. Hyperacute rejection. This is the most genuine example
of severe endothelial damage in the allogeneic transplant,
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Fig. 3 – Inhibition of classical complement activation by membrane-bound and circulating control proteins. The serum
protein C4bp neutralizes C4. DAF blocks the action of C4b, impeding digestion of C2 to C2a and C2b. MCP  acts as cofactor I,
degrading C4b to C4c and C4d. Finally, CD59 is anchored to the membrane and prevents polymerization of C9. DAF: decay
accelerating factor. MCP: membrane cofactor protein.
induced by preformed antibodies that activate comple-
ment through the classical pathway.
Once the allograft vessels are unclamped and the blood
starts ﬂowing in the transplanted organ, the antibodies
bind to HLA class I antigens expressed on the membrane
of endothelial cells of glomeruli and microvessels. Com-
plement is activated and the graft immediately takes on a
limp texture and mottled color that is usually a result of
irreversible damage.
Experimental data suggest the following pathophysiologi-
cal sequences (Fig. 6):
• The endothelial cell membrane is coated with a layerof heparan sulfate. This proteoglycan maintains a local
anticoagulant environment by activating antithrombin
III, a potent inhibitor of thrombin formation. It also
FactoC1qrs
C4
C4a
C4b
α
γ
β
α
γ
β
Fig. 4 – Evasion strategies of endothelial cells. Disappearance of 
mediated by the internal thioester.participates in the regulation of endothelial barrier
impermeability to the passage of cells and molecules
since it is part of the union between endothelial cells
and their cytoskeleton; and also through its electrical
charge it rejects the plasma coagulation factors from the
endothelial surface.
• Experimental data have shown that the exposure of
porcine endothelial cells to human xenoreactive natural
antibodies causes progressive release of heparan sulfate
from their surface mediated by enzymatic cleavage of
the protein core and/or glycosaminoglycan chains. In
contrast, the supernatant from endothelial cells exposed
to human serum for 4 h contained intact proteoglycan,
possibly reﬂecting vesiculation or cell lysis as well as
proteoglycan fragments. The cleavage and release of
C4c
C4d
iC4b
Factor Ir I
MCP acts as cofactor
α
γ
β
α
γ
β
cleaved component C4c and stable binding of fragment C4d
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Ab interaction with HLA and other 
membrane-bound molecules
Classical complement
pathway activation Ab-dependent cell-mediated cytotoxicity
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Fig. 5 – Ligation of HLA molecules by high titers of anti-HLA antibodies can generate: (1) Direct tissue damage by increasing
the expression of ﬁbroblast receptors (FGFR) and cell proliferation. (2) Activation of the classic complement pathway. (3)
Cytotoxicity mediated by antibodies and Fc receptors causing capillaritis and/or glomerulitis. FGF: ﬁbroblast growth factor.
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Fig. 6 – Sequence of events in hyperacute rejection (explanation in the text). (A) Capillaritis (Masson trichrome). Presence of
polynuclear leukocytes in the peritubular capillaries attracted by chemotaxis. (B) Interstitial hemorrhage (H&E). The release
of heparan sulfate causes intercellular gaps via which the red cells reach the interstitium. (C) Thrombotic microangiopathy
with cortical necrosis (PAS).
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rinoFig. 7 – (A) Acute humoral rejection. Transmural arteritis (ﬁb
the peritubular capillaries (Immunoﬂuorescence).
endothelial cell proteoglycans appeared to be triggered
by the binding of natural antibodies to endothelial cells
and activation of complement.57
• Loss of heparan sulfate is accompanied by alterations in
the shape and the cytoskeleton of the endothelial cells
that disrupt monolayer integrity and lead to formation
of intercellular gaps allowing the passage of cells and
molecules, causing edema and interstitial bleeding visi-
ble on biopsy58 (Fig. 6B).
The loss of the endothelial barrier effect exposes the inter-
stitial tissue VIIa complex and the plasma coagulation
factors IX and X that are activated; and in response to
thrombin, platelets express receptors for the von Wille-
brand factor and platelet aggregation is activated. This
process results in thrombotic microangiopathy (Fig. 6C).
• The tubules receive oxygen and nutrients through the
peritubular capillaries. Vascular injury causes necrosis of
tubular epithelial cells and continuation of the process
leads to tissue necrosis.
The presence of inﬂammatory cells, especially neutrophils,
in the peritubular capillaries (capillaritis) and glomeruli
(glomerulitis), is due to the chemotactic effect of the
C3a and C5a complement factors that are very powerful
opsonins attracting these cells to the site of injury, where
they secrete pro-inﬂammatory cytokines.
b. Acute humoral rejection. Promoted by a humoral mem-
ory response generated by prior exposure to HLA or other
antigens, provided by the allograft and expressed on the
endothelium of peritubular and glomerular capillaries.59–61
Rejection appears a few days after the transplant but if
the patient receives induction with anti-lymphocyte antibod-
62ies its appearance is delayed by weeks. It is produced by the
memory  response to previous exposure to HLA antigens in the
early phase of RT and in the late phase by noncompliance with
immunosuppressive treatment63 (Fig. 7).id necrosis of the vascular wall) (H&E). (B) C4d deposits in
From the standpoint of prognosis, clear differences
exist between humoral AR and hyperacute rejection. AR is
reversible, while hyperacute rejection generally is not. How-
ever, the participants are the same (DSA and endothelial cells).
Endothelial cells have the same characteristics in both cases.
The difference is in the antibodies. In hyperacute rejection
they are preformed, generally complement activators, of high
concentration and with a high afﬁnity for their alloantigen.
Conversely, a decreased expression of these qualities will trig-
ger a less severe rejection episode and we will be faced with
AR. Obviously the scale is not so simple, but at present further
explanation is not possible, since among other difﬁculties,
neither the concentration nor the afﬁnity of allospeciﬁc anti-
bodies can be measured.
Direct  complement-independent  action
Antibodies cause direct tissue damage by acting as antigen
agonists expressed on the endothelial cell membrane and
induce pro-inﬂammatory and proliferative intracellular sig-
nals in both AR and chronic rejection.
The most authentic injury resulting from this action is
transplant vasculopathy (Fig. 8A). An obliterative chronic
injury of the graft vessels caused by proliferation and hyper-
plasia of endothelial cells and smooth muscle which decreases
the vessel size and causes ischemic damage and progressive
worsening of renal function.
The pathophysiology can be summarized as: the anti-
HLA class I antibodies bind as ligands to the HLA antigens
expressed on the endothelial cells to induce stimulation of
the mTOR  pathway and S6 kinase phosphorylation (S6K) and
S6 ribosomal protein (S6RP), promoting protein synthesis
and cell proliferation.64,65 These data were reproduced in
an experimental model of murine MHC-incompatible heart
transplantation with continued administration of class I
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Fig. 8 – (A) Transplant vasculopathy. Myointimal proliferation with vascular occlusion (Masson trichrome). (B) Transplant
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ntibodies. The amount of antibody supplied correlates
ith increased phosphorylation of S6K and S6RP on
he endothelial cells of the graft capillaries. A situation
imilar to that which occurred in human heart trans-
lantation with antibody-mediated rejection in which
he S6RP phosphorylation in endocardial biopsies is
ssociated with the presence of circulating antibodies66
Fig. 9). Additionally, antibodies that act as agonists of HLA
lass I antigens induce the expression of growth factor
eceptors of ﬁbroblasts with an intensity dependent on the
evel reached in blood. In this case, the induced cellular
athway is the MEK-ERK signal that stimulates endothelial
ell proliferation67 (Fig. 9).
The effect of class II antibodies is less known, although
ata suggest cell proliferation occurs through the S6 and S6RP
ctivation pathway.64
Recent studies suggest NK cells play an important role
n the regulation of allograft acceptance or rejection.68 Their
ole is not limited to that described thus far of killing and
ytokine production, but they may be important in the devel-
pment of transplant vasculopathy. In a model in which DSA
ere infused into immunodeﬁcient Rag−/− mice that were
rafted with heart allografts to which the DSA were directed,
raft vasculopathy has been reproduced within four weeks.
he mechanism of action of NK cells in the development
f cardiac allograft vasculopathy is that they bind by their
cRs to the antibody Fc domain and are activated, secret-
ng pro-inﬂammatory cytokines that induce proliferation of
ndothelial cells and smooth muscle.69,70 The study conclu-
ions are:
. NK cells are absolutely needed for the development of
full-ﬂedged vascular lesions in the grafts, as neither NK-
depleted mice nor recipient mice genetically deﬁcient for
NK cells (Rag−/−c−/− mice) developed transplant vascu-
lopathy.ement membrane (PAS).
. A role for the Fc portion of DSA is indicated in this model.
This is because infusion of the F(ab′)2 fragment of DSA
failed to induce vasculopathy in the graft.
c. Complement is dispensable. Transplant vasculopathy can
be induced with noncomplement-ﬁxing DSA or in C3-
deﬁcient Rag−/− mice in which complement activation is
inhibited.
Others suggest that the assessment of the NK cell
immunophenotype may contribute to deﬁne signatures of
alloreactive humoral responses in renal allograft recipients.71
Recruitment  of  inﬂammatory  cells  via  Fc
receptors  (antibody-mediated  cell  immunity)
Antibody-activated endothelial cells express VCAM-1 and
ICAM-1 adhesion molecules, which promote the adhesion
of inﬂammatory cells72 that activate exocytosis of granules
containing prothrombotic mediators, such as von Wille-
brand factor and P-selectin, by triggering calcium-mediated
Weibel–Palade body exocytosis (Fig. 9). The biologically active
complement split-product C5a adds a slight but signiﬁcant
increase to antibody induction of exocytosis. Crosslinking of
HLA appears critical to stimulate exocytosis, because only
the bivalent F(ab′)2 of one class I antibody W6/32 is effec-
tive in trigging exocytosis. Ligation of MHC class I molecules
by antibodies also leads to a dose-dependent increase in
the production of monocyte chemoattractant protein-1 and
neutrophil chemoattractant growth-related oncogene  that
attract macrophages to the graft.73Transplant  glomerulopathy
This is a histologically deﬁned entity, associated with molec-
ular pathways of DSA induction that are not well known.74
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Fig. 9 – Pathophysiology of transplant vasculopathy. Antigen–antibody binding generates: (1) Increased expression of
ﬁbroblast receptors, which activate the MEK/ERK pathway and AP-1 and NF-kB, inducing cell proliferation. (2) The
nd fa
hesiWeibel–Palade bodies secrete their contents of von Willebra
Stimulation of the Rho pathway, which induces protein synt
Along with transplant vasculopathy it is the most representa-
tive entity of chronic rejection.
The histology is characterized by:
1. Multilamination and double contour of the basement
membrane, mesangial matrix expansion and glomerulitis
(light microscopy-PAS and silver staining) (Fig. 8B).
2. Loss of endothelial fenestration, inﬂammation of endothe-
lial cells and mesangial matrix expansion (electron
microscopy).
3. IgM and C3 deposits with positive C4d in varying propor-
tions (immunoﬂuorescence).
Risk factors: patient age, presence of DSA, prior acute rejec-
tion and positive C-virus serology.
The pathophysiology involves class I and II DSA, but more
often class II, DP as well as DR and DQ. Although having DQ is
considered an increased risk of transplant glomerulopathy,75
not all agree with this theory and even claim that there
are no differences between DP, DR and DQ DSA.76,77 Why
transplant glomerulopathy is related to class II antibodies is
unknown.75,78,79
Since about half the patients have no anti-HLA antibodies,
the involvement of other etiologies, particularly thrombotic
microangiopathy and hepatitis C, have been suggested.80ctor and P-selectin, which favors leukocyte recruitment. (3)
s and cell proliferation.
The  role  of  C4d  in  the  diagnosis  of  transplant
glomerulopathy
Current data on C4d deposition as a marker of humoral rejec-
tion in transplant glomerulopathy is summarized below:
1. The presence of C4d deposits in the glomerulus is useful
for diagnosis.81
2. A strong association exists between transplant glomeru-
lopathy and the presence of circulating anti-HLA antibodies
and C4d deposition in peritubular capillaries.82
3. In patients with circulating antibodies, C4d deposits can
be detected in the glomeruli, but not in the peritubular
capillaries. In this case, C4d deposition should be assessed
in parafﬁn sections, since after freezing peripheral C4d
deposits can be found in normal glomeruli.83,84
4. Detection of C4d deposits varies according to the series
and the technique used. Chronic injury from antibodies
occurs in waves  and C4d deposition may occur during peak
periods.
5. Regarding the problems posed by C4d deposition, the con-
cept of C4d-negative humoral rejection has been proposed
for cases in which light microscopy shows glomerulitis and
capillaritis.
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on-HLA  antibodies  in  humoral  rejection
 plethora of polymorphic non-HLA molecules associated
ith acute and chronic humoral rejection has been described,
ut the absence of commercial assays prevents diagnosis.
erasaki suggests that in C4d-positive cases without demon-
tration of circulating anti-HLA antibodies this possibility
hould be considered.85
The following non-HLA antibodies should be emphasized:
. MICA  antigens. The polymorphic MHC  class I-related chain
A (MICA) antigens expressed on endothelial cells have been
implicated in the pathogenesis of hyperacute, acute and
chronic allograft rejections, although no study involving
MICA antibodies has yet demonstrated donor speciﬁcity.39
. Angiotensin II AT1 receptor. In patients with pre-eclampsia
with seizures and severe hypertension, agonistic antibod-
ies against the angiotensin II AT1 receptor have been
detected in serum.86 Based on these data, in RT recipi-
ents with vascular rejection refractory to treatment and
with severe hypertension, analysis of the presence of
angiotensin II AT1 agonistic antibodies was performed. Of
20 cases, 16 had these IgG antibodies of the subclasses
IgG1 and IgG3. In vitro stimulation of vascular cells with
AT1-receptor-activating antibody induced phosphorylation
of ERK kinase and increased the DNA binding activity
of the transcription factors AP-1 and NF-B, resulting in
increased expression of proinﬂammatory cytokines, pro-
coagulatory genes and cell proliferation. Furthermore, in
a renal transplant model in rats, the administration of
antibodies against the AT1 angiotensin II receptor caused
vasculopathy, which was preventable with losartan.87
. Vimentin. This protein is part of the intermediate ﬁla-
ments of the intracellular cytoskeleton of the embryonic,
blood and endothelial cells of coronary vessels. Vimentin
monomers are wound together to form part of the support
of the intracellular organelles (mitochondria, endoplasmic
reticulum, etc.). It can induce coronary artery disease after
cardiac transplantation.88
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